ArticleNature2015
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Article in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 89 citations in OpenAlex.
- Article
- Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus.Nature communications · 2025Article
- The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection.Science advances · 2025Article
- Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus.NPJ vaccines · 2024Article
- Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona.The Journal of infectious diseases · 2023Article
- Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates.The Journal of infectious diseases · 2023Article
- Natural history of nonhuman primates after conjunctival exposure to Ebola virus.Scientific reports · 2023Article
- Lassa Virus Countermeasures.Current topics in microbiology and immunology · 2023Article
- A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.PLoS neglected tropical diseases · 2022Article
- Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center.NPJ vaccines · 2021Article
- Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment.Nature communications · 2020Article
- Vaccine platforms for the prevention of Lassa fever.Immunology letters · 2019Review
- TRIM69 Inhibits Vesicular Stomatitis Indiana Virus.Journal of virology · 2019Article
- Vesiculopolins, a New Class of Anti-Vesiculoviral Compounds, Inhibit Transcription Initiation of Vesiculoviruses.Viruses · 2019Article
- A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector.Scientific reports · 2019Article
- R7A mutation in N protein renders temperature sensitive phenotype of VSV by affecting its replication and transcription in vitro.Virus genes · 2019Article
- Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever.Scientific reports · 2019Article
- A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.Journal of virology · 2019Article
- A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.Cell host & microbe · 2019Article
- Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.Human vaccines & immunotherapeutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
The family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus. Some members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever in humans. During 2014 an unprecedented ZEBOV outbreak occurred in West Africa and is still ongoing, resulting in over 10,000 deaths, and causing global concern of uncontrolled disease. To meet this challenge a rapid-acting vaccine is needed. Many vaccine approaches have shown promise in being able to protect nonhuman primates against ZEBOV. In response to the current ZEBOV outbreak several of these vaccines have been fast tracked for human use. However, it is not known whether any of these vaccines can provide protection against the new outbreak Makona strain of ZEBOV. One of these approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEBOV glycoprotein (GP) (rVSV/ZEBOV). To address safety concerns associated with this vector, we developed two candidate, further-attenuated rVSV/ZEBOV vaccines. Both attenuated vaccines produced an approximately tenfold lower vaccine-associated viraemia compared to the first-generation vaccine and both provided complete, single-dose protection of macaques from lethal challenge with the Makona outbreak strain of ZEBOV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.